SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-20-056617
Filing Date
2020-05-05
Accepted
2020-05-05 09:35:11
Documents
60
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM10-Q tm2016851-1_10q.htm 10-Q 356525
2 EXHIBIT 31.1 tm2016851d1_ex31-1.htm EX-31.1 8979
3 EXHIBIT 31.2 tm2016851d1_ex31-2.htm EX-31.2 8938
4 EXHIBIT 32.1 tm2016851d1_ex32-1.htm EX-32.1 4002
5 EXHIBIT 32.2 tm2016851d1_ex32-2.htm EX-32.2 3909
  Complete submission text file 0001104659-20-056617.txt   2925937

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT anvs-20200331.xml EX-101.INS 454535
7 XBRL TAXONOMY EXTENSION SCHEMA anvs-20200331.xsd EX-101.SCH 45731
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE anvs-20200331_cal.xml EX-101.CAL 28814
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE anvs-20200331_def.xml EX-101.DEF 150313
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20200331_lab.xml EX-101.LAB 352878
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20200331_pre.xml EX-101.PRE 261361
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 20847186
SIC: 2834 Pharmaceutical Preparations